- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06222034
Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
April 17, 2024 updated by: Galapagos NV
An Open-label, Multiple Dose, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Filgotinib in Children and Adolescents From 8 to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis
A Study to evaluate the pharmacokinetics, safety, and tolerability in paediatric population for treating juvenile idiopathic arthritis (JIA).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Galapagos Medical Information
- Phone Number: +3215342900
- Email: medicalinfo@glpg.com
Study Locations
-
-
-
Amiens Cedex 1, France, 80054
- Recruiting
- CHU Amiens - Hopital Nord
-
Le Kremlin Bicêtre, France, 94270
- Recruiting
- Bicêtre University Hospital, Pediatric Rheumatology
-
-
-
-
-
Berlin, Germany, 13353
- Recruiting
- Children's university hospital Charité, Campus Virchow, SPZ
-
Hamburg, Germany, 22081
- Recruiting
- Hamburger Zentrum fur Kinder und Jugendrheumatologie
-
-
-
-
-
Krakow, Poland, 30-002
- Recruiting
- Malopolskie Badania Kliniczne
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitari Vall d'Hebron
-
Valencia, Spain, 46026
- Recruiting
- Hospital Universitari I Politecnic La Fe
-
-
-
-
-
London, United Kingdom, WC1N 3JH
- Not yet recruiting
- Great Ormond Street Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Participant with a body mass index (BMI) within the 5th to 95th percentiles for the age and gender (based on World Health Organization BMI charts). Participant must have a minimum weight of 15 kg.
Participant must meet the International League of Associations for Rheumatology classification for 1 of the following categories and have, according to the investigator's judgment, moderately to severely active disease that is not adequately controlled with his/her current therapy.
- Rheumatoid factor (RF)-positive polyarthritis
- RF-negative polyarthritis
- Oligoarthritis
- Psoriatic arthritis
- Enthesis-related arthritis (ERA) Note: Historical Human leukocyte antigen B-27 (HLA-B27) results are considered appropriate for ERA diagnosis during screening.
- Systemic JIA with active arthritis without active systemic features, or with active systemic features that are stable in the prior 6 months of time of enrollment
- Participant with intolerance or a history of inadequate response to at least one of the following medications for the treatment of JIA, administered for at least 12 weeks, based on current treatment guidelines: conventional synthetic disease-modifying antirheumatic drugs and biological disease-modifying antirheumatic drugs (including methotrexate) and non-steroidal anti-inflammatory drugs for ERA and psoriatic arthritis.
- Female participants of childbearing potential (i.e. who have passed menarche) must have a negative highly sensitive urine pregnancy test.
Key Exclusion Criteria:
- Participant with persistent oligoarthritis.
- Participant with undifferentiated arthritis.
- Participant with any other any other rheumatic, inflammatory, or immunologic disease (e.g. inflammatory bowel disease, hypogammaglobulinemia, systemic lupus erythematosus, or uncontrolled uveitis).
- Active infection that is clinically significant, as per judgment of the investigator.
- Participant with a history of complicated herpes zoster infection (with multi-dermatomal, disseminated, ophthalmic, or central nervous system involvement).
- Currently on any therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex, or atypical mycobacteria).
Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Filgotinib Dose A
Dose A of filgotinib mini-tablet for participants with bodyweight (BW) 15-<25 kg
|
Film-coated mini-tablets administered orally once daily
Other Names:
Commercially developed film-coated tablet administered orally once daily
Other Names:
|
Experimental: Filgotinib Dose B
Dose B of filgotinib tablet for participants with BW ≥25-<60 kg
|
Film-coated mini-tablets administered orally once daily
Other Names:
Commercially developed film-coated tablet administered orally once daily
Other Names:
|
Experimental: Filgotinib Dose C
Dose C of filgotinib tablet for participants with BW ≥60 kg
|
Film-coated mini-tablets administered orally once daily
Other Names:
Commercially developed film-coated tablet administered orally once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum observed plasma concentration at steady state of filgotinib (Cmax,ss)
Time Frame: Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10
|
Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10
|
Cmax,ss of GS-829845, major active metabolite
Time Frame: Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10
|
Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10
|
Area under the plasma concentration-time curve over the dosing interval at steady state of filgotinib (AUC0-24,ss)
Time Frame: Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10
|
Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10
|
AUC0-24,ss of GS-829845, major active metabolite
Time Frame: Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10
|
Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10
|
Area under the plasma concentration time curve over the dosing interval at steady state or the effective exposure of filgotinib (AUCeff,ss)
Time Frame: Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10
|
Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10
|
AUCeff,ss of GS-829845, major active metabolite
Time Frame: Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10
|
Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with treatment-emergent adverse events (TEAEs), TEAEs of interest, serious TEAEs, and TEAEs leading to treatment discontinuation.
Time Frame: Baseline (Day 1) up to week 96
|
Baseline (Day 1) up to week 96
|
Acceptability of the commercially developed film-coated tablets and of the minitablets as measured by the Pediatric Oral Medicine Acceptability Questionnaire for Patients (POMAQ-P).
Time Frame: Week 4 and week 12
|
Week 4 and week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Galapagos Study Director, Galapagos NV
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2024
Primary Completion (Estimated)
November 1, 2024
Study Completion (Estimated)
August 1, 2026
Study Registration Dates
First Submitted
January 4, 2024
First Submitted That Met QC Criteria
January 15, 2024
First Posted (Actual)
January 24, 2024
Study Record Updates
Last Update Posted (Actual)
April 18, 2024
Last Update Submitted That Met QC Criteria
April 17, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GLPG0634-CL-131
- 2023-505844-21-00 (Other Identifier: CTIS - euclinicaltrials.eu)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Juvenile Idiopathic Arthritis
-
University of AarhusAarhus University HospitalCompletedPolyarticular Juvenile Rheumatoid Arthritis | Systemic Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis, OligoarthritisDenmark
-
Institut National de la Santé Et de la Recherche...CompletedSystemic-Onset Juvenile Idiopathic ArthritisFrance
-
GeneScience Pharmaceuticals Co., Ltd.Not yet recruitingActive Systemic Juvenile Idiopathic ArthritisChina
-
Novartis PharmaceuticalsCompletedSystemic Juvenile Idiopathic Arthritis (SJIA)Italy, Russian Federation, Turkey, Belgium, Spain, Germany, France, Israel, Canada, United States, Hungary, Austria, Brazil, Sweden, Netherlands, Poland
-
Novartis PharmaceuticalsPediatric Rheumatology International Trials OrganizationCompletedSystemic Juvenile Idiopathic Arthritis With Active FlareUnited States, Argentina, Canada, Switzerland, Germany, Israel, South Africa, Belgium, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru
-
University of British ColumbiaUniversity of Manitoba; The Hospital for Sick Children; McGill University Health... and other collaboratorsRecruiting
-
AbbVieCompletedPolyarticular Juvenile Idiopathic Arthritis
-
NovartisCompletedArthritis, Juvenile RheumatoidItaly
-
Assistance Publique - Hôpitaux de ParisRecruitingJuvenile Idiopathic Arthritis (JIA)France
-
AbbVieRecruitingJuvenile Idiopathic Arthritis (JIA)United States, Germany, Hungary, Israel, Puerto Rico, Spain, Japan, Canada, Italy, Sweden
Clinical Trials on Filgotinib
-
Gilead SciencesGalapagos NVCompletedUlcerative ColitisUnited States, Netherlands, Israel, Spain, Taiwan, Germany, Australia, Italy, Hong Kong, India, Singapore, Canada, Korea, Republic of, United Kingdom, New Zealand, Ireland, France, Poland, Japan, Switzerland, Croatia, Belgium, Malaysia and more
-
Gilead SciencesGalapagos NVCompletedFistulizing Crohn's DiseaseUnited States, Italy, Belgium, Austria, Canada, Hungary, United Kingdom, Germany, France
-
Gilead SciencesGalapagos NVTerminatedPsoriatic ArthritisKorea, Republic of, United States, Australia, Belgium, Canada, Czechia, Hungary, Japan, Poland, Spain, Taiwan
-
Gilead SciencesGalapagos NVCompletedSmall Bowel Crohn's DiseaseUnited States, Belgium, United Kingdom, Germany, Spain, Czechia, Canada, Austria, France, Hungary, Italy, Ukraine
-
UMC UtrechtAlfasigma S.p.A.; ReumaNederland; Autoimmune Research and Collaboration HubNot yet recruitingIgG4-related Disease | Idiopathic Inflammatory Myopathies | Behcet's DiseaseNetherlands
-
Galapagos NVRecruitingUlcerative ColitisBelgium, Netherlands, France, Italy, Germany, Norway, United Kingdom, Ireland, Austria
-
Galapagos NVGilead SciencesActive, not recruitingRheumatoid ArthritisSpain, United States, Japan, Korea, Republic of, Taiwan, Belgium, India, Malaysia, Argentina, Australia, Poland, Czechia, Serbia, Germany, New Zealand, Bulgaria, Canada, Chile, France, Hong Kong, Hungary, Ireland, Israel, Italy, Mexico, R... and more
-
Gilead SciencesGalapagos NVCompletedCutaneous Lupus ErythematosusUnited States, Canada
-
Galapagos NVTerminatedPsoriatic ArthritisEstonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
-
Galapagos NVRecruitingRheumatoid ArthritisBelgium, Germany, Spain, Italy, United Kingdom, Netherlands